| Entry |
|
| Name |
EML4-ALK fusion kinase to PLCG-ERK signaling pathway
|
| Definition |
EML4-ALK -> PLCG -> IP3 -> (Ca2+,DAG) -> PKC -> RAF -> MEK -> ERK -> CCND1 |
| Expanded |
(238v1,238v2) -> (5335,5336) -> C01245 -> (C00076,C00165) -> (5578,5579,5582) -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 595 |
| Class |
|
| Type |
Variant
|
| Pathway |
|
| Disease |
| H00014 | Non-small cell lung cancer |
|
| Gene |
| 238 | ALK; ALK receptor tyrosine kinase |
| 5335 | PLCG1; phospholipase C gamma 1 |
| 5336 | PLCG2; phospholipase C gamma 2 |
| 5578 | PRKCA; protein kinase C alpha |
| 5579 | PRKCB; protein kinase C beta |
| 5582 | PRKCG; protein kinase C gamma |
| 369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
| 673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
| 5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
| 5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
| 5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
| 5594 | MAPK1; mitogen-activated protein kinase 1 |
| 5595 | MAPK3; mitogen-activated protein kinase 3 |
|
| Variant |
238v1 (EML4-ALK) EML4-ALK fusion
238v2 (EML4-ALK) First generation TKI-resistant ALK1 mutation
|
| Metabolite |
| C01245 | D-myo-Inositol 1,4,5-trisphosphate |
|
| Reference |
|
| Authors |
Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr |
| Title |
Role of HGF/MET axis in resistance of lung cancer to contemporary management. |
| Journal |
|
| Reference |
|
| Authors |
Roskoski R Jr |
| Title |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. |
| Journal |
|
| LinkDB |
|